Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

A specific blood cell type called HLA-DR2 may be required in order for RTL1000 to work. For that reason, all subjects will be tested for HLA-DR2 and only those subjects who test positive (about 50%) will undergo further tests to determine if they meet inclusion and exclusion criteria. Inclusion criteria: * Fulfill McDonald criteria for multiple sclerosis * Confirmed diagnosis of chronic progressive or relapsing-remitting multiple sclerosis * EDSS score of 0.0 to 6.5 * No clinical exacerbations within the 8 weeks before administration of RTL1000 * HLA-DR2 positive, as confirmed by study reference laboratory * Negative serum pregnancy test within 7 days of administration of RTL1000 and negative urine pregnancy test on Day 0 for all women of childbearing potential * Agreement of sexually active men and women of childbearing potential to practice a medically-approved form of contraception * Capable of and willing to provide written informed consent Exclusion Criteria: * Exposure to alemtuzumab or dacluzimab any time in the 6 months before administration of RTL1000 * Exposure to natalizumab or other drugs targeting alpha-4 integrin in the 6 months before RTL1000 administration or more than 3 doses of natalizumab or these drugs at any time. * Any prior exposure to RTL1000 * Exposure to other MS disease-modifying drugs (e.g., recombinant interferon beta and glatiramer acetate), immunosuppressant agents, or systemic corticosteroids (other than replacement doses) within the 4 weeks prior to RTL1000 administration * Exposure to chemotherapeutic immunosuppressants, including azathioprine, mycophenolate mofetil, methotrexate, cladribine, mitoxantrone, or cyclophosphamide, during the six months prior to administration of RTL1000 * Total lymphoid irradiation or bone marrow transplantation at any time * Known or suspected allergy to gadolinium * Contraindication to MRI (e.g., subject has a pacemaker or other contraindicated implanted metal devices or has claustrophobia that cannot be medically managed) * Clinically significant abnormalities in laboratory findings for hematologic, hepatic, and renal function at screening. * Significant medical diseases or conditions, including poorly controlled hypertension, cardiovascular disease, inflammatory disorders, immunodeficiency (e.g., HIV infection), renal failure, liver dysfunction, cancer (except treated basal cell carcinoma), or active infection. * History of, or current, psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent * History of alcohol or drug abuse likely to interfere with ability to comply with protocol requirements * Pregnancy or lactation